Journal article
Predicting Alzheimer disease with β-amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing
CC Rowe, P Bourgeat, KA Ellis, B Brown, YY Lim, R Mulligan, G Jones, P Maruff, M Woodward, R Price, P Robins, H Tochon-Danguy, G O'Keefe, KE Pike, P Yates, C Szoeke, O Salvado, SL Macaulay, T O'Meara, R Head Show all
Annals of Neurology | WILEY | Published : 2013
DOI: 10.1002/ana.24040
Abstract
Objective Biomarkers for Alzheimer disease (AD) can detect the disease pathology in asymptomatic subjects and individuals with mild cognitive impairment (MCI), but their cognitive prognosis remains uncertain. We aimed to determine the prognostic value of β-amyloid imaging, alone and in combination with memory performance, hippocampal atrophy, and apolipoprotein E ε4 status in nondemented, older individuals. Methods A total of 183 healthy individuals (age = 72.0 ± 7.26 years) and 87 participants with MCI (age = 73.7 ± 8.27) in the Australian Imaging, Biomarkers, and Lifestyle study of ageing were studied. Clinical reclassification was performed after 3 years, blind to biomarker findings. β-Am..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
The AIBL study of ageing was funded by the Commonwealth Scientific Industrial Research Organization (CSIRO; a publicly funded government research organization), Science Industry Endowment Fund, National Health and Medical Research Council of Australia (project grant 1011689), Alzheimer's Association, Alzheimer's Drug Discovery Foundation, and an anonymous foundation.